David Wells Buys 48,400 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director David Wells acquired 48,400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director owned 224,417 shares in the company, valued at $5,437,623.91. The trade was a 27.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Hims & Hers Health Stock Up 5.8%

Shares of NYSE HIMS opened at $25.24 on Thursday. The company has a 50 day simple moving average of $24.02 and a 200 day simple moving average of $27.59. The firm has a market cap of $5.84 billion, a PE ratio of -280.41, a price-to-earnings-growth ratio of 46.28 and a beta of 2.43. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.20 EPS. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Barclays raised their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 11th. Morgan Stanley dropped their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Needham & Company LLC raised their price target on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Finally, TD Cowen dropped their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.70.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Director David B. Wells bought 48,400 shares for about $1.17 million at $24.23 per share, increasing his stake by 27.5%. Investors often view insider buying as a bullish signal that management believes the stock is undervalued. Hims & Hers Stock Spikes — Insider Sends Strong Signal With $1 Million Buy
• Positive Sentiment: Another report highlighted the same insider purchase and noted Hims & Hers gained about 5% intraday on the news, reinforcing that the stock’s move is being driven by bullish insider sentiment. Hims & Hers Gains 5% on Insider Buying
• Neutral Sentiment: Analyst commentary comparing Hims & Hers with Tempus AI may keep attention on HIMS as an AI-healthcare growth story, but it does not appear to be a direct catalyst for the stock move today. HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?
• Negative Sentiment: Bank of America lowered its price target on HIMS to $25 from $28 and warned that the company may need a significant ramp in GLP-1 subscriber growth to meet 2026 guidance, which adds a cautionary note for investors. Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after acquiring an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares in the last quarter. Amundi increased its stake in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after acquiring an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.